When was BridGene Biosciences founded?

BridGene Biosciences was founded in 2018 and raised its 1st funding round within a year of its incorporation.

Where is BridGene Biosciences located?

BridGene Biosciences is headquartered in Sunnyvale, United States.

Who is the current CEO of BridGene Biosciences?

Ping Cao of BridGene Biosciences. They have also founded 1 company.

How many employees does BridGene Biosciences have?

As of May 31, 2026, the latest employee count at BridGene Biosciences is 31.

Is BridGene Biosciences a funded company?

BridGene Biosciences is a funded company, having raised a total of $78.5M across 5 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 15, 2018.

When was the latest funding round of BridGene Biosciences?

BridGene Biosciences' latest funding was a $***** Series B round on Oct 16, 2025, with participation from 5 investors. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $1.62B in funding in 2026 to date.

Where does BridGene Biosciences rank among its competitors?

BridGene Biosciences ranks 135th amongst 3241 active competitors, of which 873 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was BridGene Biosciences, which secured $28M in Oct, 2025.

Who are the top competitors of BridGene Biosciences?

BridGene Biosciences' top competitors include Alnylam, Spark Therapeutics and Abcellera Biologics. Among them, BridGene Biosciences secured the most recent funding round in October, 2025.

BridGene Biosciences - 2026 Company Profile, Team, Funding & Competitors

BridGene Biosciences is a series B company based in Sunnyvale (United States), founded in 2018 by Ping Cao and Irene Yuan. It operates as a Developer of small-molecule drugs for the treatment of cancer. BridGene Biosciences has raised $78.5M in funding from investors like Deyi Capital, Lapam Capital and Junson Capital. The company has 3241 active competitors, including 873 funded and 578 that have exited. Its top competitors include companies like Alnylam, Spark Therapeutics and Abcellera Biologics.

Company Details

Developer of small-molecule drugs for the treatment of cancer. The company utilizes its proprietary Chemoproteomics platform, IMTAC that enables the screening of small molecules against all the proteins in live cells to discover drug candidates for high value and hard-to-drug targets that cause diseases.

Website: www.bridgenebio.com
Social
Email ID: *****@bridgenebiosciences.com
Phone Number: +1 **********

Key Metrics

Founded Year

2018

Location

Sunnyvale, United States

Stage

Series B

Total Funding

$78.5M in 5 rounds

Latest Funding Round

Series B, Oct 16, 2025, $*****

Investors

Deyi Capital & 9 more

Ranked

135^th among 3241 active competitors

Employee Count

31 as on May 31, 2026

Similar Companies

Alnylam & 4314 more

View BridGene Biosciences' full profile

BridGene Biosciences is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
BRIDGENE BIOSCIENCES INC CIN: 830552264 , United States, Active	Dec 31, 1999	-	24 (As on Dec 31, 2024)	-
BridGene Biosciences, Inc. CIN: 83-0552264 , United States, Active	Dec 31, 2018	-	15 (As on Dec 31, 2021)	-

BridGene Biosciences has raised a total funding of $78.5M over 5 rounds. Its first funding round was on Sep 15, 2018. Its latest funding round was a Series B round on Oct 16, 2025 for $*****. 5 investors participated in its latest round. BridGene Biosciences has 10 institutional investors.

Here is the list of recent funding rounds of BridGene Biosciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 16, 2025	2714712	Series B	7249927	9370911	6306864	3883777
Jul 27, 2022	8993203	Series B	2359577	7414975	3184794	9894013
May 05, 2021	3633460	Series A	7904818	7703341	Kaitai Capital Management	3088635

Access funding benchmarks and valuations. Sign up today!

View details of BridGene Biosciences's funding rounds and investors

The founders of BridGene Biosciences are Ping Cao and Irene Yuan. Ping Cao is the CEO of BridGene Biosciences.

Here are the details of BridGene Biosciences' key team members:

Ping Cao: Co-Founder & CEO of BridGene Biosciences.
Contact Info: 1 email address
Irene Yuan: Co-Founder & Executive Vice President of BridGene Biosciences.
Contact Info: 1 email address

View details of BridGene Biosciences's Founder profiles and Board Members

BridGene Biosciences' employee count trend

BridGene Biosciences has 31 employees as of May 26. Here is BridGene Biosciences's employee count trend over the years:

Employee count trend for BridGene Biosciences

Uncover BridGene Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BridGene Biosciences include Alnylam, Spark Therapeutics and Abcellera Biologics. Here is the list of Top 10 competitors of BridGene Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	80/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
3rd	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
4th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	71/100
5th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	71/100
6th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
7th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
8th	TScan Therapeutics 1995, Boston (United States), Public	Developer of T cell therapies to harness the immune system against cancer	$180M	RA Capital Management, Novartis & 9 others	70/100
9th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	69/100
10th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
135th	BridGene Biosciences 2018, Sunnyvale (United States), Series B	Developer of small-molecule drugs for the treatment of cancer	$78.5M	ShenZhen GTJA Investment Group, GTJAI & 8 others	57/100